BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Study or Subgroup	Sacubitril/valsartan Events	Total	Control Events	Total	Weight	Risk Ratio M-H, Random, 95% CI
AWAKE-HF 2019	1	70	1	70	0.1%	1.00 [0.06, 15.67]
CLCZ696B2223	0	8	0	8		Not estimable
EVALUTE-HF 2019	2	232	1	233	0.1%	2.01 [0.18, 22.00]
Li J 2019 (1)	3	62	5	64	0.4%	0.62 [0.15, 2.48]
OUTSTEP-HF	2	310	4	311	0.3%	0.50 [0.09, 2.72]
PARADIGM-HF 2014	735	4209	848	4233	97.6%	0.87 [0.80, 0.95]
PIONEER-HF 2018	13	443	15	444	1.4%	0.87 [0.42, 1.80]
PRIME-HF 2019	1	60	0	58	0.1%	2.90 [0.12, 69.81]
Total (95% CI)		**5394**		**5421**	**100.0%**	**0.87 [0.80, 0.95]**
Total events	757		874			

Heterogeneity: Tau² = 0.00; Chi² = 1.67, df = 6 (P = 0.95); I² = 0%
Test for overall effect: Z = 3.08 (P = 0.002)